Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
MDA-MB-231 Vorinostat
3.1623
HDAC
Misc
 -0.0399 0.30688
Hs 578T Palbociclib
3.1623
CDK4/6
Cell cycle
 0.3049 0.11532
MDA-MB-231 Olaparib
3.1623
PARP
Misc
 0.8689 0.01080
MCF 10A Palbociclib
3.1623
CDK4/6
Cell cycle
 0.4544 -0.00579
BT-549 Cediranib
3.1623
VEGFR/cKIT
RTK
 0.6391 0.03522
HCC1806 Saracatinib
3.1623
SRC
MAPK/nRTK
 0.4325 0.11326
Hs 578T Cabozantinib
3.1623
VEGFR2/MET
RTK
 0.8488 0.03305
HCC1806 INK-128
3.1623
mTORC1/2
PI3K/mTOR
 0.2620 0.10078
HCC38 AZD7762
3.1623
CHK1/2
Cell cycle
 -0.3010 0.39632
MCF 10A PF-4708671
3.1623
p70S6K
PI3K/mTOR
 0.8358 -0.00533
MCF 10A INK-128
3.1623
mTORC1/2
PI3K/mTOR
 0.1716 -0.00275
Hs 578T Cediranib
3.1623
VEGFR/cKIT
RTK
 0.1560 0.19759
HCC38 Topotecan
3.1623
Topo I
Chemotherapy
 -0.4920 0.56927
MCF 10A Ceritinib
3.1623
ALK
RTK
 0.5414 0.01676
MCF 10A Pictilisib
3.1623
pan PI3K
PI3K/mTOR
 0.4105 -0.00468
HCC1806 PF-4708671
3.1623
p70S6K
PI3K/mTOR
 1.1503 -0.01604
HCC38 Vorinostat
3.1623
HDAC
Misc
 -0.0938 0.40719
MCF 10A Buparlisib
3.1623
pan PI3K
PI3K/mTOR
 0.0988 0.10554
HCC1806 Tivantinib
3.1623
MET
RTK
 -0.1869 0.48586
MDA-MB-231 TGX221
3.1623
PI3Kb
PI3K/mTOR
 0.9391 0.00782
HCC38 Bleomycin
3.1623
Radiation
Misc
 -0.1515 0.43601
MCF 10A Abemaciclib
3.1623
CDK4/6
Cell cycle
 0.2543 -0.00150
Hs 578T Dasatinib
3.1623
BCR/ABL
MAPK/nRTK
 -0.2270 0.58927
HCC38 Tivantinib
3.1623
MET
RTK
 -0.2218 0.41201
HCC38 Neratinib
3.1623
EGFR/HER2
RTK
 0.4571 0.08465